Diligence memo · auto-generated · as of July 2, 2026

Genomedx Inc.

Genomedx Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Genomedx Inc. operates in Other Health Care, based in SAN DIEGO.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Genomedx Inc. has raised $73M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $25M on 2016-02-24.

Most recent recorded round closed around 2020-05-15.

Valuation (modeled)modeled

Provath models Genomedx Inc. at approximately $176M (range $19M–$678M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.47× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 6 months.

Last raise 6.1 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 94% of Other Health Care peers (5377 compared).

Modeled value ranks above 86% of those peers.

Closest niche peers: KSMS Holdings, LLC, Infab HoldCo, Inc., Aquity Holdings, Inc., MHH Management Holdco, LLC, Earli Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.